Trial Profile
A Phase 2, Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Entinostat (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Jul 2023 Status changed from completed to discontinued.
- 25 Apr 2022 Status changed from active, no longer recruiting to completed.
- 17 Mar 2011 Planned end date changed from 1 Aug 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.